Verve Therapeutics Stock In The News
| VERV Stock | USD 5.55 0.01 0.18% |
Our overall analysis of Verve Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Verve Therapeutics. The specific impact of Verve Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Verve Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Verve Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Verve Therapeutics Backtesting and Verve Therapeutics Hype Analysis. For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Verve and other traded companies coverage with news coverage. We help investors stay connected with Verve headlines for the 22nd of March to make an informed investment decision based on correlating the impacts of news items on Verve Stock performance. Please note that trading solely based on the Verve Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Verve |
Verve Therapeutics Today Top News and Investor Outlook
Verve Therapeutics Past News Timeline
Verve Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Verve earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Verve Therapeutics that are available to investors today. That information is available publicly through Verve media outlets and privately through word of mouth or via Verve internal channels. However, regardless of the origin, that massive amount of Verve data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Verve Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Verve Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Verve Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Verve Therapeutics alpha.
Verve Largest EPS Surprises
Earnings surprises can significantly impact Verve Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.6617 | -0.59 | 0.0717 | 10 | ||
2023-03-02 | 2022-12-31 | -0.76 | -0.67 | 0.09 | 11 | ||
2025-02-27 | 2024-12-31 | -0.6705 | -0.58 | 0.0905 | 13 | ||
2024-11-05 | 2024-09-30 | -0.6877 | -0.59 | 0.0977 | 14 | ||
2022-03-14 | 2021-12-31 | -0.55 | -0.65 | -0.1 | 18 | ||
2024-05-08 | 2024-03-31 | -0.71 | -0.59 | 0.12 | 16 |
Verve Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Verve Therapeutics Stock. Current markets are strongly bearish. About 79% of major world exchanges and indexes are down. See today's market update for more information.
17th of March 2025
Disposition of 25000 shares by Politi Jason of Verve Therapeutics at 11.57 subject to Rule... at MacroaxisInsider
3rd of March 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635 at globenewswire.com
27th of February 2025
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 20... at globenewswire.com
19th of February 2025
Verve Therapeutics Trading Down 6.7 percent Whats Next at thelincolnianonline.com
7th of February 2025
Acquisition by Allison Dorval of 75000 shares of Verve Therapeutics at 6.01 subject to Rul... at MacroaxisInsider
5th of February 2025
STATE STREET CORP Reduces Stake in Verve Therapeutics Inc at gurufocus.com
3rd of February 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635 at finance.yahoo.com
31st of January 2025
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PR Newswi... at news.google.com
8th of January 2025
Acquisition by Ashe Andrew D. of 40000 shares of Verve Therapeutics subject to Rule 16b-3 at gurufocus.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Verve Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Verve Therapeutics' short interest history, or implied volatility extrapolated from Verve Therapeutics options trading.
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.